Semax

Overview

Semax is a Russian peptide derived from a fragment of ACTH, marketed as a nootropic with neuroprotective properties. It reliably raises BDNF, supports cognition, and is approved in Russia for stroke recovery, cognitive disorders, and peptic ulcers. Like other peptides, it is generally handled as a research chemical requiring reconstitution, though it is most often used intranasally.

Our Verdict

We spent real effort trying to judge Semax fairly. It has clinical approval in Russia for stroke recovery, it raises BDNF strongly, and it acts within hours of intranasal dosing. The catch is that the evidence is concentrated almost entirely in Russian-language literature, which limits Western peer review and access to raw data. Community feedback is broadly positive and the pharmacology is genuinely compelling, but how much you trust it depends on how you weigh clinical findings that have not been independently replicated.

Evidence Quality

Human trials are moderate, consisting of Russian studies in stroke and cognitive impairment with little Western replication. Animal evidence is strong, with clear BDNF upregulation and neuroprotection. Community reports are strong, consistently citing better focus, verbal fluency, and motivation. The key unknown is what sustained BDNF elevation does to the brain over the long term, which remains poorly characterized.

What the Research Shows

Clinical data report that Semax at 12-18 mg improved neurological function and motor skills in acute ischemic stroke patients. It is more stimulating than its sibling peptide Selank and is studied mainly for cognitive demand rather than anxiety. Intranasal delivery gives rapid onset, and the N-Acetyl form has a longer half-life.

Who Should Be Cautious

Some users report hair shedding, possibly tied to BDNF's effect on hair-follicle cycling. Given the stimulating profile, anyone with a history of mania or bipolar disorder should be careful.

What We Cannot Tell You

Nearly all clinical data comes from Russian institutions, and outside researchers have limited access to the underlying datasets. Independent Western replication of the stroke and cognition trials would meaningfully strengthen the case.

Community Sentiment

Across 941 community reports, sentiment is 48% positive, 36% neutral, and 15% negative. The most cited effects are focus, cognitive enhancement, and BDNF increase; the most cited side effects are hair loss, headache, irritability, and anxiety. Among 45 users who posted more than once over a median of 17 days, 12 grew more positive, 26 stayed about the same, and 7 grew more negative. There are also a few user mentions of serotonin syndrome as a safety topic.

Dosage

The typical range is 200-600 mcg intranasally, one to three times daily. N-Acetyl Semax is a more potent variant used at lower doses, and the peptide can also be injected subcutaneously.

Effectiveness

Effects are often felt within 30 minutes intranasally, results are described as reliable for cognitive enhancement, and it is frequently stacked with Selank for a more balanced profile.

Availability

Semax is sold as a research chemical by peptide suppliers, is an approved and widely used medication in Russia, and comes in both standard and N-Acetyl forms.

Cited Research (Summarized)

Russian observational work reports that early rehabilitation plus Semax raised BDNF and improved motor performance after stroke, and that 12-18 mg doses improved neurological and motor outcomes in acute ischemic stroke. Animal studies show it offsetting behavioral and biochemical damage from neonatal SSRI exposure and restoring immune balance in stressed animals. In vitro work documents its binding of copper and zinc ions and reduction of copper-induced neurotoxicity, plus its breakdown by serum enzymes. Reviews propose it as a non-stimulant ADHD option and summarize decades of data on its cognitive and anti-anxiety effects, and a meta-analysis reports reduced stroke severity and improved mobility versus placebo. The recurring caveat is that the strongest clinical findings are concentrated in Russian sources.